vs
R F INDUSTRIES LTD（RFIL）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是R F INDUSTRIES LTD的1.3倍（$30.3M vs $22.7M），R F INDUSTRIES LTD净利率更高（0.8% vs -221.3%，领先222.1%），REGENXBIO Inc.同比增速更快（43.0% vs 22.9%），R F INDUSTRIES LTD自由现金流更多（$2.0M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 29.8%）
妥思卷工业是一家总部位于美国伊利诺伊州芝加哥的糖果制造商，旗下最知名的产品包括同名的Tootsie Roll软糖以及Tootsie Pop棒棒糖，目前其品牌产品销往加拿大、墨西哥等全球超过75个国家。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
RFIL vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.3倍
$22.7M
营收增速更快
RGNX
高出20.1%
22.9%
净利率更高
RFIL
高出222.1%
-221.3%
自由现金流更多
RFIL
多$54.8M
$-52.8M
两年增速更快
RGNX
近两年复合增速
29.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $22.7M | $30.3M |
| 净利润 | $173.0K | $-67.1M |
| 毛利率 | 36.8% | — |
| 营业利润率 | 4.0% | -190.0% |
| 净利率 | 0.8% | -221.3% |
| 营收同比 | 22.9% | 43.0% |
| 净利润同比 | 172.7% | -31.2% |
| 每股收益（稀释后） | $0.01 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RFILRGNX
| Q4 25 | $22.7M | $30.3M | ||
| Q3 25 | $19.8M | $29.7M | ||
| Q2 25 | $18.9M | $21.4M | ||
| Q1 25 | $19.2M | $89.0M | ||
| Q4 24 | $18.5M | $21.2M | ||
| Q3 24 | $16.8M | $24.2M | ||
| Q2 24 | $16.1M | $22.3M | ||
| Q1 24 | $13.5M | $15.6M |
净利润RFILRGNX
| Q4 25 | $173.0K | $-67.1M | ||
| Q3 25 | $392.0K | $-61.9M | ||
| Q2 25 | $-245.0K | $-70.9M | ||
| Q1 25 | $-245.0K | $6.1M | ||
| Q4 24 | $-238.0K | $-51.2M | ||
| Q3 24 | $-705.0K | $-59.6M | ||
| Q2 24 | $-4.3M | $-53.0M | ||
| Q1 24 | $-1.4M | $-63.3M |
毛利率RFILRGNX
| Q4 25 | 36.8% | — | ||
| Q3 25 | 34.0% | — | ||
| Q2 25 | 31.5% | — | ||
| Q1 25 | 29.8% | — | ||
| Q4 24 | 31.3% | 70.2% | ||
| Q3 24 | 29.5% | 48.8% | ||
| Q2 24 | 29.9% | 52.5% | ||
| Q1 24 | 24.5% | 72.6% |
营业利润率RFILRGNX
| Q4 25 | 4.0% | -190.0% | ||
| Q3 25 | 3.6% | -176.3% | ||
| Q2 25 | 0.6% | -296.3% | ||
| Q1 25 | 0.3% | 13.6% | ||
| Q4 24 | 0.5% | -242.1% | ||
| Q3 24 | -2.5% | -256.6% | ||
| Q2 24 | -2.6% | -251.3% | ||
| Q1 24 | -15.5% | -408.8% |
净利率RFILRGNX
| Q4 25 | 0.8% | -221.3% | ||
| Q3 25 | 2.0% | -208.3% | ||
| Q2 25 | -1.3% | -331.8% | ||
| Q1 25 | -1.3% | 6.8% | ||
| Q4 24 | -1.3% | -241.3% | ||
| Q3 24 | -4.2% | -246.3% | ||
| Q2 24 | -26.7% | -237.7% | ||
| Q1 24 | -10.1% | -405.4% |
每股收益（稀释后）RFILRGNX
| Q4 25 | $0.01 | $-1.30 | ||
| Q3 25 | $0.04 | $-1.20 | ||
| Q2 25 | $-0.02 | $-1.38 | ||
| Q1 25 | $-0.02 | $0.12 | ||
| Q4 24 | $-0.02 | $-0.99 | ||
| Q3 24 | $-0.07 | $-1.17 | ||
| Q2 24 | $-0.41 | $-1.05 | ||
| Q1 24 | $-0.13 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.1M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $35.2M | $102.7M |
| 总资产 | $73.0M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RFILRGNX
| Q4 25 | $5.1M | $230.1M | ||
| Q3 25 | $3.0M | $274.2M | ||
| Q2 25 | $3.6M | $323.3M | ||
| Q1 25 | $1.3M | $267.9M | ||
| Q4 24 | $839.0K | $234.7M | ||
| Q3 24 | $1.8M | $255.5M | ||
| Q2 24 | $1.4M | $290.4M | ||
| Q1 24 | $4.5M | $338.7M |
股东权益RFILRGNX
| Q4 25 | $35.2M | $102.7M | ||
| Q3 25 | $34.8M | $161.5M | ||
| Q2 25 | $34.2M | $213.7M | ||
| Q1 25 | $34.2M | $274.2M | ||
| Q4 24 | $34.1M | $259.7M | ||
| Q3 24 | $34.1M | $301.4M | ||
| Q2 24 | $34.6M | $348.3M | ||
| Q1 24 | $38.7M | $390.7M |
总资产RFILRGNX
| Q4 25 | $73.0M | $453.0M | ||
| Q3 25 | $73.2M | $525.2M | ||
| Q2 25 | $72.7M | $581.0M | ||
| Q1 25 | $70.4M | $490.9M | ||
| Q4 24 | $71.0M | $466.0M | ||
| Q3 24 | $71.9M | $519.1M | ||
| Q2 24 | $72.8M | $569.4M | ||
| Q1 24 | $79.1M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.1M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $2.0M | $-52.8M |
| 自由现金流率自由现金流/营收 | 9.0% | -174.0% |
| 资本支出强度资本支出/营收 | 0.3% | 1.7% |
| 现金转化率经营现金流/净利润 | 12.13× | — |
| 过去12个月自由现金流最近4个季度 | $4.3M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流RFILRGNX
| Q4 25 | $2.1M | $-52.3M | ||
| Q3 25 | $-311.0K | $-56.0M | ||
| Q2 25 | $2.2M | $-49.3M | ||
| Q1 25 | $601.0K | $33.6M | ||
| Q4 24 | $-244.0K | $-31.6M | ||
| Q3 24 | $2.4M | $-40.5M | ||
| Q2 24 | $197.0K | $-45.5M | ||
| Q1 24 | $840.0K | $-55.5M |
自由现金流RFILRGNX
| Q4 25 | $2.0M | $-52.8M | ||
| Q3 25 | $-419.0K | $-56.5M | ||
| Q2 25 | $2.2M | $-49.7M | ||
| Q1 25 | $574.0K | $32.6M | ||
| Q4 24 | $-418.0K | $-32.7M | ||
| Q3 24 | $2.1M | $-40.9M | ||
| Q2 24 | $28.0K | $-46.0M | ||
| Q1 24 | $697.0K | $-56.0M |
自由现金流率RFILRGNX
| Q4 25 | 9.0% | -174.0% | ||
| Q3 25 | -2.1% | -189.9% | ||
| Q2 25 | 11.4% | -232.8% | ||
| Q1 25 | 3.0% | 36.6% | ||
| Q4 24 | -2.3% | -154.2% | ||
| Q3 24 | 12.6% | -168.9% | ||
| Q2 24 | 0.2% | -206.2% | ||
| Q1 24 | 5.2% | -358.5% |
资本支出强度RFILRGNX
| Q4 25 | 0.3% | 1.7% | ||
| Q3 25 | 0.5% | 1.7% | ||
| Q2 25 | 0.2% | 1.8% | ||
| Q1 25 | 0.1% | 1.2% | ||
| Q4 24 | 0.9% | 5.1% | ||
| Q3 24 | 1.5% | 1.3% | ||
| Q2 24 | 1.0% | 2.1% | ||
| Q1 24 | 1.1% | 3.6% |
现金转化率RFILRGNX
| Q4 25 | 12.13× | — | ||
| Q3 25 | -0.79× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RFIL
| US | $20.9M | 92% |
| Non Us | $1.8M | 8% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
